Liver Dysfunction Clinical Trial
Official title:
Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients
This study is a multicenter, single-arm, open-label, 24 weeks, and investigator-initiated clinical trial to assess the influence of CYP3A5 polymorphism on liver function abnormality and the trough level change after conversion to Advagraf® in liver transplant recipients.
All subjects who are liver transplant recipients taking Tacrolimus bid and adaptable to be
registered for the study will be classified by expressive or non-expressive CYP3A5
polymorphism genotype and Advagraf® will be administered same dose as Tacrolimus bid der day
in 24 weeks.
All subjects should check whether being registered in the hospital based on CYP3A5
polymorphism genotype during screening visit. Registered subjects will visit seven times to
the hospital during the study which includes screening visit and adverse reaction, acute
rejection, and trough level will be tested during this period. Subjects who are additionally
agreed for PK study will be hospitalized with the state of Tacrolimus bid therapy one day
ago before taking IP. On the first day of hospitalization, his/her blood will be collected.
At week 1 (plus seven days) after conversion to Advagraf®, his/her blood will be collected
for PK analysis.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02754219 -
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
|
Phase 1 | |
Terminated |
NCT01079104 -
Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units
|
N/A | |
Recruiting |
NCT00553553 -
Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery
|
N/A | |
Completed |
NCT03641872 -
A Validation Cohort for ACLF Diagnosis and Prognosis
|
||
Completed |
NCT03371537 -
Study of Hemodynamic Conditions Measured During Hepatectomy
|
||
Not yet recruiting |
NCT05559242 -
Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
|
Phase 1 | |
Recruiting |
NCT02473601 -
Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT01000337 -
Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
|
N/A | |
Completed |
NCT03155984 -
Optimizing HBV Management During Anti-CD20 Antibodies
|
||
Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
Completed |
NCT03515980 -
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
|
Phase 1 | |
Completed |
NCT01338714 -
The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function
|
Phase 3 | |
Completed |
NCT02005744 -
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
|
Phase 1 | |
Completed |
NCT01367522 -
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
|
Phase 1 | |
Recruiting |
NCT03805139 -
Role of Ajwa Derived Polyphenols in Dyslipidaemias
|
N/A | |
Enrolling by invitation |
NCT05082077 -
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
|
||
Completed |
NCT02949505 -
Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation
|
N/A | |
Completed |
NCT02991339 -
The Effects of Dexamethasone Administration on Jaundice Following Liver Resection
|
Phase 2/Phase 3 | |
Completed |
NCT02992639 -
Weight Loss Effect on Circulating Liver Enzymes
|
N/A | |
Recruiting |
NCT05793203 -
Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
|